Intellia Therapeutics (NASDAQ:NTLA) Given New $26.00 Price Target at Barclays

Intellia Therapeutics (NASDAQ:NTLA) had its price objective lowered by Barclays from $55.00 to $26.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 157.68% from the company’s current price.

NTLA has been the topic of several other research reports. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Wells Fargo & Company reduced their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday. William Blair reiterated a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday, November 18th. Canaccord Genuity Group reissued a “buy” rating and set a $90.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $42.12.

Intellia Therapeutics Price Performance

NASDAQ NTLA traded down $0.77 during mid-day trading on Friday, reaching $10.09. 4,574,403 shares of the stock were exchanged, compared to its average volume of 3,292,689. The stock has a market cap of $1.03 billion, a P/E ratio of -1.85 and a beta of 1.80. The stock has a 50 day simple moving average of $10.90 and a 200-day simple moving average of $15.72. Intellia Therapeutics has a one year low of $8.96 and a one year high of $34.87.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 29,000 shares of company stock valued at $352,551. Company insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NTLA. Mirae Asset Global Investments Co. Ltd. boosted its stake in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares in the last quarter. Capstone Investment Advisors LLC boosted its position in shares of Intellia Therapeutics by 1.4% in the 3rd quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after purchasing an additional 831 shares in the last quarter. KBC Group NV grew its stake in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after buying an additional 1,020 shares during the last quarter. Axxcess Wealth Management LLC grew its stake in shares of Intellia Therapeutics by 5.4% in the 3rd quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after buying an additional 1,044 shares during the last quarter. Finally, Ensign Peak Advisors Inc increased its position in Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after buying an additional 1,100 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.